Establishment and characteristics of a paclitaxel resistant human mammary adenocarcinoma cell subline (MCF-7/Taxol)

Chinese Pharmacological Bulletin

Volumn 24, Issue 6, 2008, Pages

  Zhang, Xiao Ping ^a,b   Tao, Yong Hui ^c   Chen, Qi Liang ^a,b   Zhang, Lian Fen ^a,b   Zhang, Rong Rong ^d   Jin, Jian ^a,b  

^a Laboratory of Molecular Pharmacology   (China)

^b JIANGNAN UNIVERSITY   (China)

^c JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

^d WUXI NO 2 PEOPLE S HOSPITAL   (China)

Author keywords

Characteristics; Mammary adenocarcinoma; Multidrug resistant; Paclitaxel; Tumor stem cell

Indexed keywords

BLEOMYCIN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN P; HYDROXYCAMPTOTHECIN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PIRARUBICIN; THIOTEPA; VINCRISTINE;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY;

EID: 47649106618     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Yang A Z, Qian J, Qin S K, et al. Establishment and characteristics of a paclitaxel resistant human lung adenocarcinoma cell subline(SPC-A1/Taxol)[J]. Chin Clin Oncol,2006,11(9):657-61.
2. Yang C Z. Some problems about the study of cancer multidrug resistance[J]. Natl Med J China,2001,81(24):1475-8.
3. Zhang H X, Guo W P, Wang Z M, et al. Establishment and characteristics of human multidrug-resistant hepatocellular carcinoma cell line(7721/Adm)[J]. Chin J Cancer,2000,19(8):748-51.
4. 3 detected by SRB method on the growth of SGC-7901 Cells[J]. J Beihua Univ (Nat Sci), 2004,5(2):122-3.
5. Li X L, Nan Y L, Zhang Y Q, Zhou X J. Determination of taxol in Canadian yew by HPLC[J]. Chin J Exp Trad Med Formul, 2006,12(3):9-11.
6. Wang L, Liu S K, Zhou Y L, Pei Q. Reversal effect of cinobufacine on adriamycin resistance human breast cancer cells[J]. Chin Pharmacol Bull,2007,23(5):677-80.
7. Mozzetti S, ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients[J]. Clin Cancer Res,2005,11(1):298-305.
8. Ueda K, Yoshida A, Amachi T. Rescent progress in P-glycoprotein research[J]. Anticancer Drug Res,2002,14(2):115-21.
9. Thomas H, Coley H M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein[J]. Cancer Control,2003,10(2):159-65.
10. Uchiyama-kokubu N, Walanabe T. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance[J]. Anticancer Drugs,2001,12(9):769-79.
11. Hosking L K, Whelan R D, Shellard S A, et al. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide[J]. Int J Cancer,1994,57(2): 259-67.
12. Mimnaugh E G, Fairchild C R, Fruehauf J P, Sinha B K. Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice[J]. Biochem Pharmacol,1991,42(2):391-402.
13. Prince M E, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma[J]. Proc Natl Acad Sci USA,2007,104(3): 973-8.